Reduction and Escalation in the Dose of Sunitinib Were Adequately Effective against Gastrointestinal Stromal Tumor of the Small Intestine-Reference-Cited by-同舟云学术

Reduction and Escalation in the Dose of Sunitinib Were Adequately Effective against Gastrointestinal Stromal Tumor of the Small Intestine

Published:2019-11-15 Issue:22 Volume:58 Page:3243-3246
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Ogata Misato¹,Satake Hironaga¹²,Ogata Takatsugu¹,Hatachi Yukimasa¹,Hara Shigeo³,Hirota Seiichi⁴,Yasui Hisateru¹

Affiliation:

1. Department of Medical Oncology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Japan

2. Cancer Treatment Center, Kansai Medical University Hospital, Japan

3. Department of Pathology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Japan

4. Department of Surgical Pathology, Hyogo College of Medicine, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/58/22/58_2806-19/_pdf

Reference14 articles.

1. 1. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480, 2002.

2. 2. Network NCC. Soft Tissue Sarcoma Ver2. 2018 [Internet]. [cited 2018 Dec 31]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf

3. 3. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368: 1329-1338, 2006.

4. 4. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 39: 1411-1419, 2008.

5. 5. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307: 1265-1272, 2012.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Imatinib/sunitinib;Reactions Weekly;2019-12